BioMarin Completes Acquisition of Inozyme Pharma to Enhance Enzyme Therapies

BioMarin Completes Acquisition of Inozyme Pharma

In a significant move to enhance its portfolio in enzyme therapies, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on July 1, 2025, that it has completed the acquisition of Inozyme Pharma, Inc. (Nasdaq: INZY). This transaction was valued at approximately $270 million, translating to $4.00 per share in an all-cash deal. The acquisition is particularly strategic as it adds INZ-701, a late-stage enzyme replacement therapy currently in development for treating ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) deficiency, a rare genetic disorder affecting bones, blood vessels, and soft tissues.

The groundwork for this acquisition began on May 16, 2025, when both companies entered a definitive merger agreement. Following this announcement, BioMarin initiated a tender offer on June 2, 2025, inviting shareholders of Inozyme to sell their shares at the offered price. The tender offer concluded as planned on June 30, 2025, and received significant support, with about 70% of the outstanding shares being tendered.

With the completion of this acquisition, BioMarin is set to bolster its leadership in developing enzyme therapies, aligning with its commitment to provide innovative treatments for genetic disorders. This merger will allow the integration of Inozyme's efforts into BioMarin’s broader pipeline, potentially accelerating the development of EX-701 and expanding treatment options for patients affected by conditions related to the pyrophosphate-adenosine pathway.

BioMarin has a history of innovation, with several commercial therapies and a robust pipeline that reflects its dedication to addressing genetic conditions. The company was founded in 1997 and has continuously sought new possibilities in drug discovery that can transform the lives of patients living with genetically defined disorders.

Inozyme Pharma, based in Boston, focuses on developing therapeutics targeting the PPi-Adenosine Pathway. Disruption of this pathway is associated with various severe diseases, including ENPP1 deficiency. The company’s lead product, INZ-701, aims to restore vital levels of pyrophosphate and adenosine in patients, offering hope for better management of the condition.

Following the merger, Inozyme shares will cease trading on the Nasdaq Global Select Market and will be delisted as a result of this consolidation. BioMarin previously engaged Goldman Sachs & Co. LLC as an exclusive financial advisor, while Cooley LLP acted as legal counsel in this transaction. Inozyme was represented by Centerview Partners LLC for financial advice, with Goodwin Procter LLP and WilmerHale LLP serving as legal counsel.

BioMarin’s commitment to advancing solutions in the biopharmaceutical landscape is evidenced through this acquisition, which not only expands their therapeutic offerings but also signifies a strategic step towards enhancing patient care in genetic disorders. Such initiatives highlight the utility of mergers and acquisitions in the biotech sector as companies strive to innovate and extend treatment capabilities for rare diseases.

For more information on BioMarin Pharmaceutical and its therapies, you can visit their official website at www.biomarin.com. Meanwhile, Inozyme Pharma continues to work on its innovative therapeutic options aimed at revolutionizing treatment pathways for patients suffering from debilitating genetic conditions.